Stock Ratings / Health Care / DRUG / options

EVO (47) PBYI (71) STTK (31) NGNE (44) ⌘ Pro Terminal →

Bright Minds Biosciences Inc. (DRUG) Options Positioning, Max Pain & Unusual Sweeps

$54.98 -3.02% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $54.58

Bright Minds Biosciences Inc. (DRUG) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $556.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DRUG Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DRUG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Bright Minds Biosciences Inc. (NASDAQ: DRUG) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $54.98 (-3.02% 1D, market cap $556.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, DRUG ranks #377 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DRUG compare to EVO and PBYI in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DRUG carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, EVO (Evotec SE) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $562.1M) and PBYI (Puma Biotechnology Inc) posts a B- grade (71/100 RQD, P/E 17.5x, ROIC 29.3%, cap $544.1M). Among the 5-stock peer group, PBYI leads on earnings multiple (17.5x) while PBYI leads on capital efficiency (29.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DRUG?

▼

For Bright Minds Biosciences Inc. (DRUG), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #377 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $54.58 (-0.73%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DRUG)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (46/100 Composite)

🔍 WHY DRUG SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0.4% FCF Margin ($15.6M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$54.01-0.4% Next Q

Q2 (-2Q)

Grade D$53.82-5.1% Next Q

Q3 (-1Q)

Grade D$51.09+7.6% Next Q

Current

Grade D$54.98-6.1% Hist 90D α

Trajectory: E (38) → D (46)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DRUG Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DRUG currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($58.77) and Max Pain ($57.73) forces dealer call-delta covering toward $129.94.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DRUG• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “DRUG Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 46%NO 54%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (DRUG)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for DRUG.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DRUG)

✓Walkthrough of DRUG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DRUG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.97%▼ DESCENDING CHANNEL

2026-11-02O $55.32H $56.69L $54.98C $54.98VOL 67.6K

RES: $82.52SUP: $45.10SMA50: $58.77SMA200: $73.10

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DRUG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DRUG Butterfly Map → + Track DRUG →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DRUG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DRUG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DRUG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DRUG)

Health Care Rank #377 of 1016 ⚔️ EVO vs DRUG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DRUG vs. EVO, PBYI, STTK, NGNE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Bright Minds Biosciences Inc. (DRUG) ranks #377 by composite RQD confidence (46/100, grade D) and #430 by equity capitalization ($556.7M). Within this direct 5-issuer industry benchmark cohort, PBYI leads on earnings valuation at 17.5x trailing P/E, while PBYI leads on capital efficiency and profitability with 29.3% ROIC and 74.5% gross margin. PBYI currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with DRUG at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DRUG ACTIVE Bright Minds Biosciences Inc.	D	46/100	—	—	—	-3.02%	$556.7M	Benchmark Subject
EVO Evotec SE	D	47/100	—	—	—	-3.16%	$562.1M	/evo-vs-drug →
PBYI Puma Biotechnology Inc	B-	71/100	17.5x	74.5%	29.3%	-0.95%	$544.1M	/pbyi-vs-drug →
STTK Shattuck Labs Inc.	E	31/100	—	—	-35.0%	-2.80%	$574.1M	/sttk-vs-drug →
NGNE Neurogene Inc.	D	44/100	—	—	-35.0%	-4.41%	$576.7M	/ngne-vs-drug →

2. DRUG Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Bright Minds Biosciences Inc. (DRUG) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $556.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. DRUG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DRUG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does DRUG compare to EVO and PBYI in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for DRUG?

Where is DRUG trading relative to its 50-day, 200-day, and 52-week technical levels?

DRUG last traded at $54.98 (-3.02% on volume of 95,831 shares), positioning the stock -6.45% below its 50-day simple moving average ($58.77) and -24.79% below its 200-day simple moving average ($73.10). Across its 52-week range of $47.23 to $123.75, DRUG sits at the 10.1% percentile with a 14-day RSI of 53.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($48.11 to $61.85).

DRUG Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is DRUG's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for DRUG.

Direct Sub-Reports: DRUG RQD Cockpit DRUG 12M Forecast DRUG Earnings & Move DRUG Dividends & DRIP DRUG Insiders & 13F DRUG Whale Options DRUG Profit Sankey DRUG News & Why

ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

DRUG — Bright Minds Biosciences Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:15:39Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, DRUG scores 46 out of 100, grading D and carrying the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

Fundamental Cash Engine (12 / 20): Per the Roarable RQD rating, this pillar reflects ROIC of 0% and FCF yield of 0%. Investor implication: the rating shows no measured cash return on capital, so there is no current cash-generation support for the valuation.
Whale 13F Flow (5 / 20): Per the Roarable RQD rating, institutional accumulation and options positioning score weakly. Investor implication: the rating indicates limited evidence of sustained institutional conviction.
Insider Conviction (9 / 20): Per the Roarable RQD rating, SEC Form 4 and Congressional PTR cluster flow scores weakly. Investor implication: insider-flow evidence does not offer a strong positive signal in this rating.
Macro Regime Fit (7 / 20): Per the Roarable RQD rating, beta is 1.0 with weak sector-sensitivity scoring. Investor implication: the rating does not identify a favorable macro-regime alignment.
Forensic Balance Sheet (13 / 20): Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 6/9, and Debt/Equity is 0.5. Investor implication: this is the strongest pillar, indicating a comparatively stable balance-sheet profile relative to the other pillars, though it does not offset weak cash-return metrics.

Taken together, the rating frames DRUG as a name where balance-sheet metrics are the relative strength while cash returns, institutional flow, and macro fit are weak. Potential upside drivers are not established by the rating itself; the rating's verdict is a warning on distribution risk. Valuation tradeoffs cannot be fully assessed because P/E, EV/EBITDA, and EPS are not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, the dominant item is a trial regulatory event: the BMB-101 Phase 2 trial was reported as placed on an FDA partial hold, appearing across several outlets including marketscreener.com and Mugglehead Investment Magazine. Other items reference the BMB-101 NOVA study and Prader-Willi Syndrome conferences, and a reported 4.98% share-price dip. All feed items carry a YELLOW light and MARKET WIRE impact label.

Risk watch items: the partial hold on the BMB-101 seizure trial is the primary catalyst flagged in the feed. Per the Butterfly Supply-Chain Graph, no proprietary signals are present.

Open Questions

What are the company's products, revenue sources, and commercial stage? The profile identifies only sector and industry.
What is the scope and timeline of the FDA partial hold on the BMB-101 trial, and what are the implications for the NOVA study?
Why are P/E, EPS, and EV/EBITDA unavailable, and what do reported financial statements show for revenue, operating income, and cash burn?
What is the composition of institutional holdings and any 13F or insider activity, given the holders section is empty?
What drives the 52-week range from $47.23 to $123.75, and how does current price of 56.69 compare to that history?

DRUG Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Bright Minds Biosciences Inc. (DRUG) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DRUG Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 16h ago

Bright Minds Biosciences And 2 More Canadian Biotech Stocks

Yahoo Finance report covering Bright Minds Biosciences Inc. (DRUG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 19h ago

Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Up 6.6% - Here's Why

MarketBeat report covering Bright Minds Biosciences Inc. (DRUG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE marketscreener.com • 22h ago

Bright Minds Biosciences' BMB-101 Phase 2 Trial Placed on FDA Partial Hold

marketscreener.com report covering Bright Minds Biosciences Inc. (DRUG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Mugglehead Investment Magazine • 1d ago

Bright Minds Biosciences reports FDA partial hold on BMB‑101 seizure trial

Mugglehead Investment Magazine report covering Bright Minds Biosciences Inc. (DRUG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE kalkine.ca • 1d ago

Bright Minds Biosciences Stock Dips 4.98% Ahead of Prader-Willi Syndrome Conferences as BMB-101 NOVA Study Advances (CN:DRUG)

kalkine.ca report covering Bright Minds Biosciences Inc. (DRUG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Bright Minds Biosciences Inc. (DRUG) Seasonal Returns Chart

Yahoo! Finance Canada report covering Bright Minds Biosciences Inc. (DRUG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

The FDA put Bright Minds' planned seizure study partly on hold, citing toxicity findings in mice.

Stock Titan report covering Bright Minds Biosciences Inc. (DRUG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Bright Minds Biosciences Inc. (NASDAQ:DRUG) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages

MarketBeat report covering Bright Minds Biosciences Inc. (DRUG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DRUG Bull vs. Bear Conversation Board — What's Your Call at $54.98?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DRUG 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $61.23 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is DRUG (D • RQD 46/100) a Buy at $56.69?

Welcome to the DRUG (Bright Minds Biosciences Inc.) Roar Pit. Current RQD Composite is 46/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $43.08 (-24.0%)

Spot @ $56.69

Pump the brakes on DRUG — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on DRUG, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Bright Minds Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $72.00 (+27.0%)

Spot @ $56.69

DRUG cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on DRUG, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $56.69 (52-wk range $47.23 - $123.75), any beat on forward guidance forces shorts and underweight funds to chase.